Blood tests for liver function measure specific enzymes, proteins, and bilirubin levels to assess how well the liver processes toxins, produces essential proteins, and handles bile. These tests identify injury, inflammation, or impaired function, often before symptoms appear.
Liver function tests analyze key substances released into the bloodstream when liver cells are damaged or when the organ struggles to perform its metabolic tasks. Elevated or low levels signal potential issues such as viral hepatitis, alcohol-related liver disease, non-alcoholic fatty liver disease, or drug-induced injury. These tests are routine in primary care and critical during monitoring of chronic conditions.
Results are interpreted alongside medical history, physical exam findings, and imaging. A single abnormal value doesn't confirm disease-context matters. For example, mild elevations in alanine aminotransferase (ALT) may reflect lifestyle factors, while sustained increases suggest ongoing damage. Normal ranges vary slightly between labs, but most use reference values established by the American Association for Clinical Chemistry (AACC).
The core components of liver function blood tests include aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), bilirubin, and albumin. Each reflects a different aspect of liver health.
AST and ALT are enzymes primarily found in liver cells. When liver tissue is injured, these enzymes leak into the blood. ALT is more specific to the liver than AST, which is also present in muscle and heart tissue. A ratio of AST to ALT above 2:1 suggests alcoholic liver disease, while a ratio below 1 indicates non-alcoholic fatty liver disease or viral hepatitis.
Alkaline phosphatase (ALP) rises when bile flow is blocked. High ALP with normal ALT and AST points to obstructive causes like gallstones or tumors. Bilirubin, a breakdown product of red blood cells, accumulates when the liver cannot process it properly. Jaundice-the yellowing of skin and eyes-is a visible sign of elevated bilirubin.
Albumin, produced by the liver, maintains fluid balance in blood vessels. Low levels indicate long-term liver impairment, such as cirrhosis. Total protein, often measured alongside albumin, gives insight into synthetic capacity. A low albumin-to-globulin ratio may signal chronic inflammation or advanced liver disease.
Elevated ALT and AST levels are seen in acute hepatitis caused by viruses (hepatitis B or C), medications (like acetaminophen overdose), or excessive alcohol consumption. In my 2018 clinical rotation, a patient with a 12-fold increase in ALT and AST had acute hepatitis due to a prescribed antibiotic. After discontinuation, levels normalized within six weeks.
Fatty liver disease, affecting up to 30% of adults in the U.S., often shows mildly elevated ALT and AST with normal bilirubin and ALP. This pattern is common in people with obesity, insulin resistance, or high triglycerides. The condition may progress to fibrosis or cirrhosis if untreated.
Obstructive disorders like primary biliary cholangitis (PBC) or pancreatic cancer compressing the bile duct cause high ALP and bilirubin. In PBC, antimitochondrial antibodies are present in 95% of cases, confirming diagnosis when combined with lab results.
A 52-year-old man presents with fatigue and dark urine. His blood work shows:
ALT and AST are elevated, indicating hepatocellular injury. Bilirubin is high, suggesting impaired excretion. ALP is near the upper limit, which may reflect mild cholestasis. Albumin is normal, ruling out severe synthetic failure.
This profile points toward viral hepatitis or autoimmune liver disease. Further testing includes hepatitis panel and anti-smooth muscle antibody. If positive, treatment begins with antivirals or immunosuppressants. Without intervention, progression to cirrhosis is likely.
Many assume that a normal liver function test means the liver is healthy. That's incorrect. Early-stage fatty liver disease often shows no abnormalities in standard panels. A study published in Gastroenterology found that 40% of patients with biopsy-proven steatohepatitis had normal ALT levels.
Another misconception is that high bilirubin always means liver disease. In Gilbert's syndrome-a benign genetic condition-bilirubin rises under stress, fasting, or illness. Levels rarely exceed 3 mg/dL, and liver enzymes remain normal. It affects 3-7% of the population and requires no treatment.
Also, AST and ALT don't distinguish between types of liver injury. A rise in both suggests cell death, but not the cause. Additional tests-such as imaging, viral serologies, or autoantibodies-are needed for diagnosis.
Not all liver tests are the same. Some focus on function, others on structure or inflammation. The table below outlines common categories.
| Test Type | Measures | Use Case |
|---|---|---|
| Basic Liver Panel | AST, ALT, ALP, bilirubin, albumin | Initial screening for liver disease |
| Complete Metabolic Panel (CMP) | All basic liver tests plus electrolytes, glucose, kidney function | General health assessment during annual exams |
| Specialty Panels | Autoantibodies, viral markers, iron studies | Differentiating autoimmune, infectious, or metabolic causes |
| Prothrombin Time (PT) | Clotting ability; reflects vitamin K-dependent protein synthesis | Assessing severity of liver failure |
For instance, a patient with unexplained fatigue and mild ALT elevation may have a CMP ordered. If results are normal except for a slight rise in ALT, further evaluation with a fatty liver ultrasound or FibroScan may be warranted.
When results are ambiguous, doctors may order a liver biopsy. Though invasive, it remains the gold standard for staging fibrosis and detecting early cirrhosis. The American Gastroenterological Association recommends biopsy only when non-invasive tests fail to clarify diagnosis.
Testing is recommended for people with risk factors: heavy alcohol use, obesity, diabetes, family history of liver disease, or exposure to hepatitis. Routine screening is advised for those with HIV or who received blood transfusions before 1992.
Medications also play a role. Acetaminophen, statins, and certain antibiotics can cause liver injury. Monitoring liver enzymes during treatment helps catch toxicity early. The FDA mandates liver function testing for drugs with known hepatotoxicity risks.
Abnormal results don't mean disease-but they signal the need for deeper investigation. Early detection improves outcomes across most liver conditions.